Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Vertex Pharmaceuticals Incorporated”

980 pharma patents match "Vertex Pharmaceuticals Incorporated" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 980
Index total 30,257
Page 4 / 41

Quick answer

This filtered view shows 980 pharmaceutical patents matching "Vertex Pharmaceuticals Incorporated" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

980 results for “Vertex Pharmaceuticals Incorporated” · 30,257 patents in full index Clear search

  1. US 11566236

    Materials and methods for treatment of hemoglobinopathies

    Vertex Pharmaceuticals Incorporated · Granted Jan 31, 2023 · Expires Jan 26, 2043

    granted

  2. US 11564916

    Pharmaceutical composition and administrations thereof

    Vertex Pharmaceuticals Incorporated · Granted Jan 31, 2023 · Expires Jan 26, 2043

    granted

  3. US 11529337

    Method of treating pain

    Vertex Pharmaceuticals Incorporated · Granted Dec 20, 2022 · Expires Dec 15, 2042

    granted

  4. US 11525120

    Stem cell derived islet differentiation

    Vertex Pharmaceuticals Incorporated · Granted Dec 13, 2022 · Expires Dec 8, 2042

    granted

  5. US 11517564

    Methods of treatment for cystic fibrosis

    Vertex Pharmaceuticals Incorporated · Granted Dec 6, 2022 · Expires Dec 1, 2042

    granted

  6. US 11485739

    Compounds useful as inhibitors of ATR kinase

    Vertex Pharmaceuticals Incorporated · Granted Nov 1, 2022 · Expires Oct 27, 2042

    granted

  7. US 11471398

    Devices and methods for delivering therapeutics

    Vertex Pharmaceuticals Incorporated · Granted Oct 18, 2022 · Expires Oct 13, 2042

    granted

  8. US 11466256

    Stem cell derived islet differentiation

    Vertex Pharmaceuticals Incorporated · Granted Oct 11, 2022 · Expires Oct 6, 2042

    granted

  9. US 11464774

    Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Oct 11, 2022 · Expires Oct 6, 2042

    granted

  10. US 11459587

    Materials and methods for treatment of pain related disorders

    Vertex Pharmaceuticals Incorporated · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted

  11. US 11453655

    Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

    Vertex Pharmaceuticals Incorporated · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted

  12. US 11440907

    Antiproliferation compounds and uses thereof

    Vertex Pharmaceuticals Incorporated · Granted Sep 13, 2022 · Expires Sep 8, 2042

    granted

  13. US 11426407

    Modulators of cystic fibrosis transmembrane conductance regulator

    Vertex Pharmaceuticals Incorporated · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  14. US 11427838

    Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders

    Vertex Pharmaceuticals Incorporated · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  15. US 11414439

    Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

    Vertex Pharmaceuticals Incorporated · Granted Aug 16, 2022 · Expires Aug 11, 2042

    granted

  16. US 11390600

    Crystalline forms of C21H22Cl2N4O2

    Vertex Pharmaceuticals Incorporated · Granted Jul 19, 2022 · Expires Jul 14, 2042

    granted

  17. US 11370798

    Compounds useful as inhibitors of ATR kinase

    Vertex Pharmaceuticals Incorporated · Granted Jun 28, 2022 · Expires Jun 23, 2042

    granted

  18. US 11369692

    Materials and methods for treatment of Duchenne Muscular Dystrophy

    Vertex Pharmaceuticals Incorporated · Granted Jun 28, 2022 · Expires Jun 23, 2042

    granted

  19. US 11358977

    Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels

    Vertex Pharmaceuticals Incorporated · Granted Jun 14, 2022 · Expires Jun 9, 2042

    granted

  20. US 11345700

    Methods of preparing inhibitors of influenza viruses replication

    Vertex Pharmaceuticals Incorporated · Granted May 31, 2022 · Expires May 26, 2042

    granted

  21. US 11291662

    Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

    Vertex Pharmaceuticals Incorporated · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted

  22. US 11268077

    Materials and methods for treatment of hemoglobinopathies

    Vertex Pharmaceuticals Incorporated · Granted Mar 8, 2022 · Expires Mar 3, 2042

    granted

  23. US 11253509

    Methods of treatment for cystic fibrosis

    Vertex Pharmaceuticals Incorporated · Granted Feb 22, 2022 · Expires Feb 17, 2042

    granted

  24. US 11203571

    Sulfonamides as modulators of sodium channels

    Vertex Pharmaceuticals Incorporated · Granted Dec 21, 2021 · Expires Dec 16, 2041

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.